Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort.
CDK4/6 inhibitors
Elderly population
Metastatic breast cancer
Real world
Toxicity
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
22 Mar 2024
22 Mar 2024
Historique:
received:
17
10
2023
accepted:
24
01
2024
medline:
23
3
2024
pubmed:
23
3
2024
entrez:
23
3
2024
Statut:
aheadofprint
Résumé
Cyclin-dependent kinases 4/6 inhibitors (CDK 4/6i) combined with endocrine therapy have become the gold standard in hormone receptor-positive (HR +) HER2-negative (HER2-) metastatic breast cancer (MBC). However, there is a significant lack of data regarding the efficacy and safety of these treatments in elderly patients. We present the results of a real-world data (RWD) cohort stratified by age at treatment initiation (≥ 70 years compared to patients < 70 years). Clinico-pathological data of HR + HER2- MBC patients who were candidates for CDK4/6i therapy between January 2017 and December 2020 at the Institut Català d'Oncologia (Spain) were retrospectively collected. The primary goal was to assess Progression-Free Survival (PFS), Overall Survival (OS), and safety outcomes within this patient population. A total of 274 patients with MBC who received CDK4/6i treatment were included in the study. Among them, 84 patients (30.8%) were aged ≥ 70 years, with a mean age of 75, while 190 patients (69.2%) were under the age of 70, with a mean age of 55.7 years. The most frequently observed grade 3-4 toxicity was neutropenia, with similar rates in both the < 70 group (43.9%) and the ≥ 70 group (47.9%) (p = 0.728). The median Progression-Free Survival (mPFS) for the first-line CDK4/6i treatment was 22 months (95% CI, 15.4-39.8) in the < 70 group and 20.8 months (95% CI 11.2-NR) in the ≥ 70 group (p = 0.67). Similarly, the median PFS for the second-line CDK4/6i treatment was 10.4 months (95% CI, 7.4-15.1) and 7.1 months (95% CI 4.4-21.3) (p = 0.79), respectively. Median overall survival (mOS) was not reached either for the first- and second-line treatment. Our RWD suggests that elderly patients, when compared to those under 70, experience similar survival outcomes and exhibit comparable tolerance for CDK4/6i therapy.
Identifiants
pubmed: 38519708
doi: 10.1007/s12094-024-03399-3
pii: 10.1007/s12094-024-03399-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–36.
doi: 10.1056/NEJMoa1607303
pubmed: 27959613
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5(1):1–8. https://doi.org/10.1038/s41523-018-0097-z .
doi: 10.1038/s41523-018-0097-z
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–7.
doi: 10.1093/annonc/mdy155
pubmed: 29718092
Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, erbb2-negative breast cancer that progressed on endocrine therapy - MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6(1):116–24.
doi: 10.1001/jamaoncol.2019.4782
pubmed: 31563959
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with Ribociclib plus Letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50.
doi: 10.1056/NEJMoa2114663
pubmed: 35263519
Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, et al. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021;186(2):417–28. https://doi.org/10.1007/s10549-020-06029-y .
doi: 10.1007/s10549-020-06029-y
pubmed: 33392835
pmcid: 7990838
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with Palbociclib and Fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–36.
doi: 10.1056/NEJMoa1810527
pubmed: 30345905
Abdel-Razeq H, Rous FA, Abuhijla F, Abdel-Razeq N, Edaily S. Breast cancer in geriatric patients: current landscape and future prospects. Clin Interv Aging. 2022;17:1445–60.
doi: 10.2147/CIA.S365497
pubmed: 36199974
pmcid: 9527811
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.
doi: 10.3322/caac.21583
pubmed: 31577379
Aura L, Utchins FH, Oseph J, Nger MU, Ohn J, Rowley JC, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–7. https://doi.org/10.1056/NEJM199912303412706 .
doi: 10.1056/NEJM199912303412706
Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021;22(7):e327–40.
doi: 10.1016/S1470-2045(20)30741-5
pubmed: 34000244
Clifton K, Min Y, Kimmel J, Litton J, Tripathy D, Karuturi M. Progression free survival (PFS) and toxicities of palbociclib in a geriatric population HHS public access keywords metastatic breast cancer; CDK 4/6 inhibitors; Hormone receptor-positive breast cancer. Treatment toxicity Breast Cancer Res Treat. 2019;175(3):667–74.
doi: 10.1007/s10549-019-05181-4
pubmed: 30835017
Torregrosa-Maicas MD, Del Barco-Berrón S, Cotes-Sanchís A, Lema-Roso L, Servitja-Tormo S, Gironés-Sarrió R. Expert consensus to optimize the treatment of elderly patients with luminal metastatic breast cancer. Clin Transl Oncol. 2022;24:1033–46. https://doi.org/10.1007/s12094-021-02766-8 .
doi: 10.1007/s12094-021-02766-8
pubmed: 35103908
pmcid: 9107453
Battisti NML. Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: young international society of geriatric oncology review paper. Ther Adv Vaccines. 2018;9(6):259–61.
Diering M, Mitchell F. HHS Public Access. Physiol Behav. 2018;176(1):139–48.
Rugo HS, Turner NC, Finn RS, Joy AA, Verma S, Harbeck N. Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018;101:123–33. https://doi.org/10.1016/j.ejca.2018.05.017 .
doi: 10.1016/j.ejca.2018.05.017
pubmed: 30053671
Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018;167(3):659–69. https://doi.org/10.1007/s10549-017-4523-y .
doi: 10.1007/s10549-017-4523-y
pubmed: 29058175
Freedman RA, Tolaney SM. Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/ − advanced breast cancer: a review. Breast Cancer Res Treat. 2018;167(3):607–14.
doi: 10.1007/s10549-017-4560-6
pubmed: 29103175
Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH, et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021;22:e327–40.
doi: 10.1016/S1470-2045(20)30741-5
pubmed: 34000244
Poorvu PD, Vaz-Luis I, Freedman RA, Lin NU, Barry WT, Winer EP, et al. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the united states. Breast Cancer Res Treat. 2018;168(3):727–37.
doi: 10.1007/s10549-018-4659-4
pubmed: 29332137
Goyal RK, Chen H, Abughosh SM, Holmes HM, Candrilli SD, Johnson ML. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer. 2023;129(7):1051–63.
doi: 10.1002/cncr.34675
pubmed: 36760031
Mycock K, Zhan L, Hart K, Taylor-Stokes G, Milligan G, Atkinson C, et al. Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study. Future Oncol. 2022;18(3):349–62.
doi: 10.2217/fon-2021-0716
pubmed: 34842454
Fountzilas E, Koliou GA, Vozikis A, Rapti V, Nikolakopoulos A, Boutis A, et al. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: The experience of the Hellenic Cooperative Oncology Gr. ESMO Open. 2020;5(4):1–9.
doi: 10.1136/esmoopen-2020-000774
DeSouza K, Yeo D, Diossy M, Umar S, Gore E, Trivedi S, et al. Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC). J Clin Oncol. 2021;39:e13031. https://doi.org/10.1200/JCO.2021.39.15_suppl.e13031 .
doi: 10.1200/JCO.2021.39.15_suppl.e13031
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–39.
doi: 10.1016/S1470-2045(15)00613-0
pubmed: 26947331
Cardoso Borges F, Alves da Costa F, Ramos A, Ramos C, Bernardo C, Brito C, et al. Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study. Breast. 2022;62:135–43.
doi: 10.1016/j.breast.2022.02.005
pubmed: 35182993
pmcid: 8859011
Laohavinij S, Paul V, Maneenil K. Survival and prognostic factors of metastatic breast cancer. J Med Assoc Thai. 2017;100(Suppl 1):S16-26.
pubmed: 29927171
Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer: A population-based study. Br J Cancer. 2014;110(3):565–72.
doi: 10.1038/bjc.2013.756
pubmed: 24300977
Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, et al. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer. JAMA Netw Open. 2020;3(1): e1918160.
doi: 10.1001/jamanetworkopen.2019.18160
pubmed: 31899528
pmcid: 6991239
De Azambuja E, Cardoso F, De Castro G, Colozza M, Mano MS, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br J Cancer. 2007;96(10):1504–13.
doi: 10.1038/sj.bjc.6603756
pubmed: 17453008
pmcid: 2359936
Endo Y, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Iwasa M, et al. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol. 2011;16(5):512–8.
doi: 10.1007/s10147-011-0215-5
pubmed: 21431343
Anderson H, Hills M, Zabaglo L, A’Hern R, Leary AF, Haynes BP, et al. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Ann Oncol. 2011;22(8):1770–6.
doi: 10.1093/annonc/mdq700
pubmed: 21285137
Prat A, Chaudhury A, Solovieff N, Paré L, Martinez D, Chic N, et al. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. J Clin Oncol. 2021;39:1458–67.
doi: 10.1200/JCO.20.02977
pubmed: 33769862
pmcid: 8196091
Ismail RK, van Breeschoten J, Wouters MWJM, van Dartel M, van der Flier S, Reyners AKL, et al. Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. Breast. 2021;60(263):271. https://doi.org/10.1016/j.breast.2021.11.013 .
doi: 10.1016/j.breast.2021.11.013
Kovač A, Matos E, Kuhar CG, Čakš M, Ovčariček T, Mencinger M, et al. Efficacy and safety of selective cyclin-dependent kinases 4/6 inhibitors in hormone-receptor-positive, HER2-negative advanced breast cancer – results from a real-world setting. Cancer Treat Res Commun. 2020;25:100201. https://doi.org/10.1016/j.ctarc.2020.100201 .
doi: 10.1016/j.ctarc.2020.100201
pubmed: 32979704
Bui TBV, Burgers DMT, Agterof MJ, van de Garde EMW. Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy. Breast Cancer (Auckl). 2019;13:1178223418823238.
pubmed: 30675102
Kish JK, Ward MA, Garofalo D, Ahmed HV, McRoy L, Laney J, et al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res. 2018;20(1):1–8.
doi: 10.1186/s13058-018-0958-2
Waller J, Mitra D, Mycock K, Taylor-Stokes G, Milligan G, Zhan L, et al. Real-world treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer in Argentina: The IRIS study. J Glob Oncol. 2019;2019(5):1–10.